These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19569068)

  • 1. Upstream high-dose tirofiban does not reduce myocardial infarct size in patients undergoing primary percutaneous coronary intervention: a magnetic resonance imaging pilot study.
    Song YB; Hahn JY; Gwon HC; Kim JH; Lee SY; Choe YH; Choi SH; Choi JH; Lee SH
    Clin Cardiol; 2009 Jun; 32(6):321-6. PubMed ID: 19569068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shen J; Zhang Q; Zhang RY; Zhang JS; Hu J; Yang ZK; Zheng AF; Zhang X; Shen WF
    Coron Artery Dis; 2008 Jun; 19(4):271-7. PubMed ID: 18480672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracoronary bolus-only compared with intravenous bolus plus infusion of tirofiban application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Kırma C; Erkol A; Pala S; Oduncu V; Dündar C; İzgi A; Tigen K; Gibson CM
    Catheter Cardiovasc Interv; 2012 Jan; 79(1):59-67. PubMed ID: 21523892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.
    Hermanides RS; van Werkum JW; Ottervanger JP; Breet NJ; Gosselink AT; van Houwelingen KG; Dambrink JH; Hamm C; ten Berg JM; van 't Hof AW;
    Catheter Cardiovasc Interv; 2012 May; 79(6):956-64. PubMed ID: 22162050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Valgimigli M; Campo G; Malagutti P; Anselmi M; Bolognese L; Ribichini F; Boccuzzi G; de Cesare N; Rodriguez AE; Russo F; Moreno R; Biondi-Zoccai G; Penzo C; Díaz Fernández JF; Parrinello G; Ferrari R
    JACC Cardiovasc Interv; 2011 Jan; 4(1):51-62. PubMed ID: 21251629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial.
    Patel MR; Worthley SG; Stebbins A; Dill T; Rademakers FE; Valeti US; Barsness GW; Van de Werf F; Hamm CW; Armstrong PW; Granger CB; Kim RJ
    JACC Cardiovasc Imaging; 2010 Jan; 3(1):52-60. PubMed ID: 20129531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical outcomes and safety of primary percutaneous coronary intervention combined with tirofiban therapy in patients with acute ST-segment elevation myocardial infarction].
    Shen J; Zhang Q; Zhang RY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Nov; 35(11):1005-9. PubMed ID: 18269820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial).
    Taglieri N; Saia F; Guiducci V; Tondi S; Conrotto F; Marrozzini C; Rocchi G; Biagini E; Reggiani ML; Giacometti P; Piovaccari G; Manari A; Marzocchi A;
    Am J Cardiol; 2009 Mar; 103(6):785-90. PubMed ID: 19268732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Short- or long-outcome of early tirofiban in ST-segment elevated acute myocardial infarction undergoing elective percutaneous coronary intervention].
    Zhang Y; Gao C; Li M; Liu H; Wang X; Yang H; Wang X; Zhu Z; Hu D
    Zhonghua Nei Ke Za Zhi; 2014 Apr; 53(4):273-7. PubMed ID: 24857299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.
    Talarico GP; Brancati M; Burzotta F; Porto I; Trani C; De Vita M; Todaro D; Giammarinaro M; Leone AM; Niccoli G; Andreotti F; Mazzari MA; Schiavoni G; Crea F
    J Cardiovasc Med (Hagerstown); 2009 Mar; 10(3):245-51. PubMed ID: 19262211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term effect of upstream administration in comparison to deferred injection of tirofiban on patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Jia Z; Guo M; Zhang YQ; Liang HQ; Song Y
    J Interv Cardiol; 2013 Aug; 26(4):332-9. PubMed ID: 23844823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of pre-hospital-initiated facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention in acute myocardial infarction very early after symptom onset: the LIPSIA-STEMI trial (Leipzig immediate prehospital facilitated angioplasty in ST-segment myocardial infarction).
    Thiele H; Eitel I; Meinberg C; Desch S; Leuschner A; Pfeiffer D; Hartmann A; Lotze U; Strauss W; Schuler G;
    JACC Cardiovasc Interv; 2011 Jun; 4(6):605-14. PubMed ID: 21700245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular function. The randomised Leipzig Immediate PercutaneouS Coronary Intervention Abciximab i.v. versus i.c. in ST-Elevation Myocardial Infarction Trial (LIPSIAbciximab-STEMI).
    Eitel I; Friedenberger J; Fuernau G; Dumjahn A; Desch S; Schuler G; Thiele H
    Clin Res Cardiol; 2011 May; 100(5):425-32. PubMed ID: 21125288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and feasibility of a novel dosing regimen of tirofiban administered in patients with acute myocardial infarction with ST elevation before primary coronary angioplasty: a pilot study.
    Kochman W; Dobrzycki S; Nowak KS; Chlopicki S; Kralisz P; Prokopczuk P; Bachorzewska-Gajewska H; Gugala K; Niewada M; Mezynski G; Poniatowski B; Korecki J; Musial WJ
    J Thromb Thrombolysis; 2004 Apr; 17(2):127-31. PubMed ID: 15306748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty.
    Bilsel T; Akbulut T; Yesilcimen K; Terzi S; Sayar N; Dayi SU; Akgoz H; Ergelen M; Ciloglu F
    Heart Vessels; 2006 Mar; 21(2):102-7. PubMed ID: 16550311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction.
    Martínez-Ríos MA; Rosas M; González H; Peña-Duque MA; Martínez-Sánchez C; Gaspar J; García H; Gaxiola E; Delgado L; Carrillo J; Leyva JL; Lupi E;
    Am J Cardiol; 2004 Feb; 93(3):280-7. PubMed ID: 14759375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy comparison of combined intracoronary administration of high-dose adenosine and tirofiban versus intracoronary tirofiban during primary percutaneous coronary intervention in patients with acute myocardial infarction].
    Tong ZC; Li Q; Chen M; Miao GB; Wei Y; Li FO; Zhao H; Zhang JJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Oct; 41(10):839-44. PubMed ID: 24377889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Facilitated PCI by combination fibrinolysis or upstream tirofiban in acute ST-segment elevation myocardial infarction: results of the Alteplase and Tirofiban in Acute Myocardial Infarction (ATAMI) trial.
    Peters S; Truemmel M; Koehler B
    Int J Cardiol; 2008 Nov; 130(2):235-40. PubMed ID: 18055037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MGUard versus bAre-metal stents plus manual thRombectomy in ST-elevation myocarDial infarction pAtieNts-(GUARDIAN) trial: study design and rationale.
    Cassese S; Esposito G; Mauro C; Varbella F; Carraturo A; Montinaro A; Cirillo P; Galasso G; Rapacciuolo A; Piscione F
    Catheter Cardiovasc Interv; 2012 Jun; 79(7):1118-26. PubMed ID: 22105879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
    JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.